Abbott Laboratories is preparing for higher tariffs, including a 50% US levy on Indian imports, impacting the company by nearly $200 million. CEO Robert Ford is focusing on mitigating tariffs through long-term investments in manufacturing and supply chains. Abbott’s strategy of US and international manufacturing sites helps buffer against foreign exchange swings.

To combat the impact of tariffs, Abbott announced a $500 million investment to boost US manufacturing and unveiled plans for new sites in Georgia and Ohio. Despite solid second-quarter results, including revenue of $11.14 billion and adjusted earnings per share of $1.26, Abbott adjusted its full-year EPS guidance to $5.10 to $5.20 due to tariffs.

Ford emphasized aligning demand with production and adapting to the changing economic backdrop. Additionally, Abbott is addressing blood shortages in the US by partnering with the Big Ten Conference to increase donations. The company’s diversified manufacturing sites and strategic investments aim to navigate tariff challenges.

Read more at Yahoo Finance: Abbott Laboratories CEO warns tariffs are here to stay, points to new US investments